{"id":"idh","name":"IDH1 / IDH2","symbol":"IDH1, IDH2","route":"/targets/idh/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138413","uniprot":"https://www.uniprot.org/uniprotkb/O75874/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O75874","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2007625","open-targets":"https://platform.opentargets.org/target/ENSG00000138413","civic":"https://civicdb.org/genes/3417/summary","oncokb":"https://www.oncokb.org/gene/IDH1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IDH1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IDH1","depmap":"https://depmap.org/portal/gene/IDH1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000138413-IDH1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3417","omim":"https://www.omim.org/entry/147700"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182054","uniprot":"https://www.uniprot.org/uniprotkb/P48735/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P48735","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3991501","open-targets":"https://platform.opentargets.org/target/ENSG00000182054","civic":"https://civicdb.org/genes/3418/summary","oncokb":"https://www.oncokb.org/gene/IDH2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IDH2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IDH2","depmap":"https://depmap.org/portal/gene/IDH2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000182054-IDH2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3418","omim":"https://www.omim.org/entry/147650"}],"products":[{"id":"enasidenib","name":"Enasidenib","status":"approved","modality":"Small-molecule IDH2 inhibitor","route":"/drugs/enasidenib/"},{"id":"hmpl-306","name":"HMPL-306","status":"phase-3","modality":"small molecule","route":"/drugs/hmpl-306/"},{"id":"ivosidenib","name":"Ivosidenib","status":"approved","modality":"Small-molecule IDH1 inhibitor","route":"/drugs/ivosidenib/"},{"id":"olutasidenib","name":"Olutasidenib","status":"approved","modality":"Small-molecule IDH1 inhibitor","route":"/drugs/olutasidenib/"},{"id":"oncomine-dx-target-test","name":"Oncomine Dx Target Test","status":"approved","modality":"Tissue NGS companion diagnostic test (multi-gene panel)","route":"/drugs/oncomine-dx-target-test/"},{"id":"safusidenib","name":"Safusidenib","status":"phase-3","modality":"small molecule inhibitor","route":"/drugs/safusidenib/"},{"id":"tqb3454","name":"TQB3454","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/tqb3454/"},{"id":"vorasidenib","name":"Vorasidenib","status":"approved","modality":"Small-molecule IDH1/2 inhibitor","route":"/drugs/vorasidenib/"}],"trials":[{"id":"indigo","name":"INDIGO","nct":"NCT04164901","phase":"3","status":"positive"},{"id":"agile","name":"AGILE","nct":"NCT03173248","phase":"3","status":"positive"},{"id":"claridhy","name":"ClarIDHy","nct":"NCT02989857","phase":"3","status":"positive"},{"id":"nct05987358","name":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma","nct":"NCT05987358","phase":"3","status":"active"},{"id":"nct06387069","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","nct":"NCT06387069","phase":"3","status":"recruiting"},{"id":"nct05876754","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","nct":"NCT05876754","phase":"3","status":"active"},{"id":"nct05907057","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","nct":"NCT05907057","phase":"3","status":"recruiting"},{"id":"nct07745296","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","nct":"NCT07745296","phase":"3","status":"planned"},{"id":"nct06127407","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","nct":"NCT06127407","phase":"3","status":"recruiting"},{"id":"safir-abc10","name":"SAFIR-ABC10","nct":"NCT05615818","phase":"3","status":"recruiting"},{"id":"nct05303519","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","nct":"NCT05303519","phase":"3","status":"recruiting"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"beat-aml-master-trial","name":"Beat AML Master Trial","nct":"NCT03013998","phase":"platform","status":"recruiting"},{"id":"nct04458272","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","nct":"NCT04458272","phase":"2","status":"active"},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","nct":"NCT07282262","phase":"2","status":"recruiting"},{"id":"nct06593548","name":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","nct":"NCT06593548","phase":"2","status":"planned"},{"id":"nct06161974","name":"Study of Olutasidenib and Temozolomide in HGG","nct":"NCT06161974","phase":"2","status":"recruiting"}],"pathways":["cancer-metabolism","epigenetic-reprogramming","glioma-signalling","glutamine-metabolism","idh-2hg"],"companies":["bms","hutchmed","nuvation-bio","rigel-pharmaceuticals","servier","sino-biopharm","thermo-fisher"],"keyPapers":["paper-indigo-nejm-2023","paper-mody-biliary-ctdna-profiling-jco-po-2019","paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","paper-javle-biliary-ngs-cancer-2016","paper-tcga-molecular-taxonomy-primary-prostate-cell-2015"],"hotspots":[{"label":"R132H","position":132,"kind":"other","frequency":"About 90% of IDH1 mutations in glioma","drugs":["vorasidenib","ivosidenib","olutasidenib"]},{"label":"R132C / R132G / R132S / R132L","position":132,"kind":"other","drugs":["ivosidenib","olutasidenib","vorasidenib"]},{"label":"IDH2 R140Q / R172K (paired gene)","position":140,"kind":"other","drugs":["enasidenib","vorasidenib"]}],"openQuestions":[{"id":"idh-glioma-timing","question":"When should vorasidenib be started in IDH-mutant glioma, and can it delay or replace radiotherapy and chemotherapy?","stage":"clinical","actor":"clinic","source":{"label":"INDIGO, NEJM 2023","url":"https://doi.org/10.1056/NEJMoa2304194"}}],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"idh1-abbott","name":"Abbott RealTime IDH1","cutoff":"Mutation detected (ivosidenib, AML)"},{"id":"idh2-abbott","name":"Abbott RealTime IDH2","cutoff":"Mutation detected (enasidenib, AML)"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}